Xencor, Inc.

Yoon Kyung Kim

Alex Nisthal

Matthew J Bernett

Seung Yup Chu

Sung-Hyung Lee

John R Desjarlais

Gregory L Moore

Rumana Rashid

Kendra N Avery

Jing Qi

Matthew S Faber

Chad Borchert

Umesh Muchhal

Rajat Varma

Michael Hedvat

Juan Diaz

Provided herein are novel CLDN6 binding domains, and anti-CLDN6×anti-CD3 antibodies that include such CLDN6 binding domains. Also provided herein are methods of using such antibodies for the treatment of CLDN6-associated cancers.

Heterodimeric antibodies that bind CD3 and CLDN6

The present invention provides untargeted and targeted IL-10-Fc fusion proteins, compositions and methods of use thereof. The targeted IL-10-Fc fusion proteins includes those that bind PD-1, TIGIT, CD8 and NKG2D.

Untargeted and targeted IL-10 Fc-fusion proteins

Provided herein are novel CLDN6 binding domains, and anti-CLDN6&#xd7;anti-CD3 antibodies that include such CLDN6 binding domains. Also provided herein are methods of using such antibodies for the treatment of CLDN6-associated cancers.

The present invention is directed to antibodies, including novel antigen binding domains and heterodimeric antibodies, that bind Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (ENPP3).

Heterodimeric antibodies that bind ENPP3 and CD3

Growing community of inventors

Pomona, CA, United States of America

Yoon Kyung Kim